Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Public ClinicalTrials.gov record NCT00105313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
Study identification
- NCT ID
- NCT00105313
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 80 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2005 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 14, 2007
Started 2005
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Cancer Center | Los Angeles | California | 90033 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center, Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc | Tampa | Florida | 33612 | — |
| University of Maryland School of Medicine, Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Tufts New England Medical Center | Boston | Massachusetts | 02111 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27517 | — |
| Kimmel Cancer Center, Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00105313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2007 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00105313 live on ClinicalTrials.gov.